Cadron 2005.

Methods	Randomised Phase III trial
Participants	24 women with histologically confirmed cervical cancer with distant metastases after surgery or recurrence after radiotherapy
Interventions	Arm 1: cisplatin 37.5 mg/m2 iv d1‐2 q28 Arm 2: cisplatin 37.5 mg/m2 iv d1‐2 and Ifosfamide 2 g/m2 iv d1‐2, mesna 0.5 g/m2, 5‐fluorouracil 500 mg/m2 d1‐2, folinic acid 30 mg/m2 d1‐2 q28
Outcomes	Response rates Toxicity (WHO) OS
Notes	3 patients ineligible (did not receive chemotherapy owing to rapid progression). ITT analysis performed. Trial stopped early owing to poor accrual
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not documented
Allocation concealment (selection bias)	Unclear risk	Not documented
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not documented but OS unlikely to be affected by blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing outcome data
Selective reporting (reporting bias)	Low risk	Published report included all pre‐specified outcomes
Other bias	Low risk	No hint at any other possible biases